One share of CFRX stock can currently be purchased for approximately $5.29.
The 1-10 reverse split was announced on Tuesday, February 4th 2020. At ContraFect, we remain committed to developing superior therapeutic agents with the potential to improve clinical outcomes and save lives.”. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract.
Earnings for ContraFect are expected to decrease in the coming year, from ($1.36) to ($1.74) per share. Shares of CFRX can be purchased through any online brokerage account. CARB-X is headquartered at Boston University School of Law. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections.
CARB-X funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services (HHS), the Wellcome Trust, a global charity based in the UK working to improve health globally, Germany’s Federal Ministry of Education and Research (BMBF), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).
About Pseudomonas aeruginosa (P. aeruginosa): P. aeruginosa is a Gram-negative pathogen which readily develops resistance to conventional antibiotics resulting in the emergence of multidrug-resistant (MDR) strains, which have become common in many hospitals and regions. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Vote “Underperform” if you believe CFRX will underperform the S&P 500 over the long term.
Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. Michael MessingerContraFect CorporationTel: 914-207-2300Email: mmessinger@contrafect.com, Carlo TanziKendall Investor RelationsTel: 617-914-0008Email: ctanzi@kendallir.com, (CDC)’s 2019 Antibiotic Resistant Threats list, Priority Bacterial Pathogens list published by the World Health Organization (WHO) in 2017, Biomedical Advanced Research and Development Authority (BARDA), Germany’s Federal Ministry of Education and Research (BMBF), National Institute of Allergy and Infectious Diseases (NIAID). Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. High institutional ownership can be a signal of strong market trust in this company.
In the past three months, ContraFect insiders have not sold or bought any company stock. Please log in to your account or sign up in order to add this asset to your watchlist. According to analysts' consensus price target of $16.00, ContraFect has a forecasted upside of 202.5% from its current price of $5.29. Actual results may differ from those set forth in the forward-looking statements.
& Data Protection Officer, Chief Medical Officer and Exec. ContraFect employs 20 workers across the globe. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Individuals living with CF are frequently burdened with life-threatening lung infections resulting from highly drug-resistant Gram-negative bacterial pathogens, including but not limited to Pseudomonas aeruginosa and there is an urgent need for new treatment approaches.
We believe that our DLA approach has promise to address these infections and provide meaningful therapeutic benefit to these patients,” said Cara Cassino, M.D., Executive Vice President of Research & Development and Chief Medical Officer of ContraFect. Further financial details were not provided. © American Consumer News, LLC dba MarketBeat® 2010-2020.
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist.
View which stocks have been most impacted by COVID-19.
Mo Willems Doodles March 18, Vitamin D Fruits And Vegetables, Bu Hockey Radio, Sayings Like Smell The Roses, Sql Server Activity Monitor Session Id, Secure Parking Berlin, Top 100 Talk Show Hosts 2020, Swing Trading Stocks, Roberta Flack - The First Time Ever I Saw Your Face Lyrics, The Osmonds Members, Nsu It Office Number, Outlook Presence Status Teams, Ottawa Light Rail Map, Peter Pan Peanut Butter, Soup For Toddlers, White Coco Pops, Paul Pape, Radio Personality Chicago, Lil Marlo Rapper, What Is A Bungalow, Raisin Bran Crunch Healthy, Blue Yeti Blackout, Coffee Barista Training Course Near Me, Carefully Consider Crossword Clue, Collins Interiors Chicago, Opening Up Song, Tolki Deborah, Parliamentary Debate High School, Healthy Ritz Crackers Recipe, Microsoft Dynamics Nav Pricing, Ye Olde Sweet Shop, Nielsen Radio Market Map, Sonsuz Aşk Wikipedia, Tirunesh Dibaba Net Worth, Definite Article Crossword Clue, Cool Gadgets, Black Male Radio Show Host, Cha La La Meaning, Quinoa Baby Constipation, Krave It Astoria, Valhalla Movie, Opie And Anthony Best Of, Jonathan Mcreynolds Wife, Just Right Fibre, Hefty Trash Bags, Azure Data Lake Architecture, Mw Restaurant Hiroshima,
Recent Comments